Layth A. Mimish, M. Bakhshi, J. Buraiki,

Slides:



Advertisements
Similar presentations
Copyleft Clinical Trial Results. You Must Redistribute Slides PEPCAD II ISR Study Paclitaxel-eluting devices: randomized comparison of the SeQuent™ please.
Advertisements

Bifurcation stenting. Crush technique. LAD / Diagonal 68 yr old male
AVE Micro Stent KFSH & RC Experience with 6 months Angiographic Follow Up Layth A. Mimish, M. Bakhshi, F. Al-Nozha, A. Kinsara, O. Amoudi, J. Buraiki,
Complications of HSRA Layth A. Mimish Consultant Cardiologist Cardiovascular Consultants Group Jeddah, Saudi Arabia.
Directional Coronary Atherectomy KFSH & RC Experience Layth A. Mimish, J. Buraiki, M. E. Fawzy, B. Dunn, M. Bakhshi, B. Dajani.
Plaque Debulking Prior to Stenting Dr. Layth A. Mimish The Cardiovascular Consultants Group Jeddah, Saudi Arabia.
30 th Annual Meeting of The Egyptian Society of Cardiology.
Rotablation or Balloon Immediate and 6 month results of a trial in patients with chronic total coronary occlusion Layth A. Mimish, M. Bakhshi, J. Buraiki,
29th ANNUAL SCIENTIFIC SESSIONS – SCA&I
CORONARY PRESSURE MEASURENT AND FRACTIONAL FLOW RESERVE
Call for CASES Staged PCI in a patient with multivessel coronary disease disqualified from CABG. Pawel Buszman, MD, FESC, FSCAI Marcin Debinski, MD Krzysztof.
Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total.
C. Graidis, D. Dimitriadis, A. Ntatsios, V. Karasavvides
As presented by Patrick W. Serruys, MD, PhD, FACC Principal Investigator Thoraxcentre - Erasmus University Rotterdam, The Netherlands PISCES Paclitaxel.
Featuring CTO Complex-PCI by Trans-radial Approach CTO Case review 5 French TRI CTO of right coronary artery -5 F Launcher guiding Catheter (right Judkins.
AICT 2010-Athens Interventional Cardiovascular Therapeutics XI 8-9 OCTOBER 2010 Divani Caravel Hotel, Αthens EARLY CLINICAL OUTCOMES AFTER PROMUS ELEMENT.
Alternative Approach Trans-Ulnar Approach Feasibility of Percutaneous Coronary Intervention Via Transulnar Artery Approach in Selected Patients with Coronary.
FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary.
A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.
LONG-TERM CLINICAL OUTCOMES AFTER REPEAT DRUG-ELUTING STENT IMPLANTATION FOR IN DRUG-ELUTING STENT RESTENOSIS. C. Graidis, D. Dimitriadis, A. Ntatsios,
ROTAXUS A Prospective, Randomized Trial of High-Speed Rotational Atherectomy Prior to Paclitaxel-Eluting Stent Implantation in Complex Calcified Coronary.
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
Endeavor 4: A Randomized Comparison of a Zotarolimus- Eluting Stent and a Paclitaxel- Eluting Stent in Patients with Coronary Artery Disease Martin B.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
Hybrid Off-Pump Revascularization; Early & Midterm Results 서울대학교병원 흉부외과 황 호영, 조 광리, 김 기봉.
Ms. Leonardo Roever Coronary Stents. Coronary Artery Disease Leading cause of death in United States for men and women Caused by buildup of plaque in.
End points in PTCA trials. A successful angioplasty is defined as the reduction of a minimum stenosis diameter to
Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at The American College.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Percutaneous Treatment of Protected and Unprotected.
Two-Year Outcomes in Real-World Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent in the PROMUS Element Plus US Post-Approval.
Revascularization of the Heart
The Endocross Enabler-P: First in-Human Results
The OPTIMAX first-in-man study Mid-term clinical outcome of Titanium-Nitride-Oxide-coated Cobalt Chromium stents in patients with de novo coronary artery.
Ospedale San Raffaele, Milan, Italy
Interesting Case Presentation
Use of Laser When the Balloon Cannot Cross
Guideliner related stent stripping
(DES)+BVS +DCB for long diffuse LAD disease
Angiographic Features of Atherosclerotic Superficial Femoral Artery Disease in Diabetics and Non-diabetics Presenting with Claudication Atif Mohammad,
Procedural factors associated with PCI-related ischemic stroke
PRISM-PLUS: Demographics of Patients With Diabetes
David J. Cohen, M.D., M.Sc. Director of Cardiovascular Research
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.
BVS Expand: First Results of Wide Clinical Applications
The XIENCE V EXCEED Study
Subintimal Tracking and Reentry for CTO STAR Method
Stent Thrombosis Rates in Contemporary Clinical Practice: Insight from a Large Australian Multi-centre Registry BP Yan*, TJ Kiernan, SJ Duffy, DJ Clark,
Session Date: 28th Nov’14 Session Time: 14:30 – 16:00
MACE Trial Rationale, Study Design, and Current Status
Catheter-Based Treatment of Coronary Artery Disease
Impact of calcium on procedural and clinical outcomes in lesions treated with bioresorbable vascular scaffolds - A prospective BRS registry study  Jiang.
TAXUS II and IV: two-year follow-up
American College of Cardiology Presented by Dr. Stephan Windecker
REALITY: 8 month results
Kyoto University Hospital, Japan
Presented at ACC 2003 Late Breaking Clinical Trials
SIRIUS: A U.S. Multicenter, Randomized, Double-Blind Study of the SIRolImUS-Eluting Stent in De Novo Native Coronary Lesions Presented at TCT 2002.
Myocardial Staining (TMPG 1)  Post-Stent in AMI
Hellenic PCI Registry Organization - Structure - Directions - Initial Recordings Georgios I. Papaioannou, MD, MPH, FACC,
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
Presented at TCT 2006.
Martin B. Leon, David R. Holmes, Dean J. Kereiakes, Jeffrey J
Impact of Diabetes Mellitus on Long-term Outcomes in the
Maintenance of Long-Term Clinical Benefit with
DEScover: One-Year Clinical Results
Ahmed A. Khattab, MD For the German Cypher Registry Investigators
Atlantic Cardiovascular Patient Outcomes Research Team
The American College of Cardiology Presented by Dr. A. Abazid
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
Presentation transcript:

Does Adjuvant Stenting After Coronary Rotablation Affect Restenosis Rate ! Layth A. Mimish, M. Bakhshi, J. Buraiki, A. Patel, K. Niazi, M. E. Fawzy, B. Dajani, B. Dunn K.F.S.H. & R.C. Riyadh, Saudi Arabia 1 1 1 1

The Goal of The Study Retrospective analysis of all cases who underwent conary revascularization with high speed rotational atherectomy from October 1993 - October 1997 Comparison of angiographic restenosis rates between patients who had HSRA +ballooning, and those who had additional stenting at the end of the procedure 2 2 2 2

Indications of Rotablation Calcification in the coronary lesion on floroscopy Inability to dilate with high atmospheric pressures Inability to cross the lesion with 1.5 mm balloon Participation in the Effect of Debulking on Restenoses Study (EDRESS) 3 3 3 3

Indications of Stenting Coronary dissection unresolved by prolonged balloon inflaton Residual stenosis more than 40% Part of the EDRESS protocol 4 4 4 4

Rotablation 10,000 U IV Heparin before procedure Small Burr Size with larger Burrs if needed Multiple short passes No significant drop in RPM Multiple doses of I.C. NTG and Verapamil Ballooning in all cases 5 5 5 5

Stenting Ticlopidine 250 mg ACT 250-300 14-16 Atmospheres deployment pressure Multiple post deployment angiographic views Sheath removal within 3 hrs. Ticlopidine BID, ASA for 1 month 6 6 6 6

Demographic Data October 1993-1997, 183 cases 147 males and 36 females Mean age 57+-11 years LAD 102, Diagonal 2, Intermediate 2, Circumflex/OM 27, RCA 50 cases Lesion type B-C 84% Stenting in 72 cases 7 7 7 7

Rotablation Mean Burr Size 1.9 +- 0.3 mm Mean number of passes 4+-2 Ablation time 99+-59 sec All lesion were dilated with a balloon post HSRA Success rate 95% 8 8 8 8

Demographic &clinical data Rotablation Rota+Stenting No. 109 Age 58.5+-10 M/F 82/27 Hx MI 55/109 QMI 40/55 Hx PTCA 40/109 73 55.3+-11 63/10 48/73 43/48 11/73 9 9 9

Demographic &clinical data Rotablation Rota+Stenting LAD 64/109 36/73 Cx/OM 16/109 8/73 RCA 24/109 27/73 Total Occlusion 22/109 9/73 Size 2.9+-0.5 3.2+-0.3 Type A 24 29 Type B 76 24 Type C 9 20 10 10 10

Demographic &clinical data Rotablation Rota+Stenting Burr size 1.8+-0.3 No. Burrs 1.2+-0.5 No. Passes 3.5+-1.7 Ablation 84+-46 Ca ++ 69 Failed Balloon 9 2.1+-0.3 1.2+-0.5 3.5+-1.7 126+-63 26 3 11 11 11

Demographic &clinical data Rotablation Rota+Stenting Success 101(93%) Failure 8 Death 2 (1.8%) Acute MI 2 CABG 4 Dissection 17 Non QMI 3 72(98.6%) 3 1 6 12 12 12

6 Months Angiographic follow up Available on 90% of patients who completed 6 months after the procedure Restenoses in the total group was 38.7% Restenoses in the stented group was 34.3% Restenoses in the non-stented group was 42.5% 13 13 13 13

Conclusion There was 12.9% reduction in restenoses in stented group Total numbers were small Mean vessel size was larger than average Restenoses remains high even with stenting 14 14 14 14